Sidley Represents Opus Genetics in US$155 Million Financing With Oberland Capital

Sidley represented Opus Genetics, Inc., a clinical-stage gene therapy company focused on inherited retinal diseases, in connection with a strategic financing agreement with Oberland Capital Management LLC. The transaction provides Opus with access to up to US$155 million in largely non-dilutive capital through a structured note facility, along with a US$5 million equity investment, and is expected to extend the company’s cash runway through 2029. The financing will support the continued advancement of Opus’s gene therapy pipeline and its efforts toward clinical development, manufacturing, and potential commercialization. Oberland Capital is a private investment firm focusing exclusively on investments in the global healthcare industry.

More information about the transaction is available here.

The Sidley team was led by Adriana Tibbitts and Asher Rubin (Technology and Life Sciences Transactions), and Angela Fontana and Adam Nelson (Global Finance), and included Pietro Fontana, Allison Satyr, and Mimi Mallory (Global Finance); Carla Teodoro and John Ekblad (Investment Funds); Tara Lancaster (Tax); Nick DeAngelis (M&A); Collin Marshall (Technology and Life Sciences Transactions); Torrey Cope (Food, Drug and Medical Device); Eric Winwood (Employee Benefits and Executive Compensation); and Robert Mandell (Capital Markets).